TG Therapeutics, Inc. (NASDAQ:TGTX) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Sunday.

A number of other equities research analysts have also issued reports on TGTX. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research note on Saturday, June 17th. Zacks Investment Research raised TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of TG Therapeutics in a research report on Monday, June 5th. Raymond James Financial, Inc. reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Friday, April 21st. Finally, ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.67.

Shares of TG Therapeutics (NASDAQ TGTX) traded up 1.40% during mid-day trading on Friday, reaching $10.85. The company’s stock had a trading volume of 1,111,744 shares. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35. The company’s market cap is $668.97 million. The company has a 50-day moving average price of $11.64 and a 200 day moving average price of $8.75.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. TG Therapeutics had a negative return on equity of 135.31% and a negative net margin of 60,613.16%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. Equities analysts expect that TG Therapeutics will post ($1.79) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/16/bidaskclub-upgrades-tg-therapeutics-inc-nasdaqtgtx-to-sell.html.

In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction on Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the sale, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at approximately $5,295,075.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 16.70% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. FMR LLC raised its position in TG Therapeutics by 70.2% in the first quarter. FMR LLC now owns 6,451,713 shares of the biopharmaceutical company’s stock valued at $75,162,000 after buying an additional 2,660,949 shares during the last quarter. Vanguard Group Inc. raised its position in TG Therapeutics by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,790,583 shares of the biopharmaceutical company’s stock valued at $20,860,000 after buying an additional 246,404 shares during the last quarter. Jennison Associates LLC bought a new position in TG Therapeutics during the first quarter valued at approximately $16,034,000. Columbus Circle Investors raised its position in TG Therapeutics by 29.3% in the first quarter. Columbus Circle Investors now owns 1,004,421 shares of the biopharmaceutical company’s stock valued at $11,702,000 after buying an additional 227,722 shares during the last quarter. Finally, State Street Corp raised its position in TG Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 679,115 shares of the biopharmaceutical company’s stock valued at $3,157,000 after buying an additional 42,760 shares during the last quarter. 46.27% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.